Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pi-CARM1-TAT
- Development stage
- Preclinical
- Lead developer
- Xiamen University
- Modality
- Peptides
01
Overview
Pi-CARM1-TAT is a cell-permeable peptide inhibitor designed to target Coactivator-associated arginine methyltransferase 1 (CARM1), also known as PRMT4. CARM1 is an epigenetic modulator that plays a pivotal role in the progression of various cancers, particularly breast cancer, by regulating the expression of oncogenic estrogen receptor alpha (ERα) target genes and type I interferon-induced genes. The peptide consists of the Pi-CARM1 inhibitor sequence conjugated to the Trans-Activator of Transcription (TAT) cell-penetrating peptide to facilitate intracellular delivery. In preclinical models, Pi-CARM1-TAT has demonstrated the ability to suppress breast cancer cell proliferation, reduce tumor growth, and overcome resistance to endocrine therapies. It also exhibits synergistic effects when combined with standard treatments like etoposide or endocrine therapy drugs.
- Other names
- Pi-CARM1Pi-CARM-1Pi-CARM 1TAT-modified Pi-CARM1Pi-CARM1 peptidePi-CARM-1 peptidePi-CARM 1 peptide
02
Targets
PRMT4 (Protein arginine N-methyltransferase 4)
Beyond the preview
Go deeper on Pi-CARM1-TAT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pi-CARM1-TAT.